162 related articles for article (PubMed ID: 35626061)
1. Diagnostic Validation of a Comprehensive Targeted Panel for Broad Mutational and Biomarker Analysis in Solid Tumors.
Froyen G; Geerdens E; Berden S; Cruys B; Maes B
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626061
[TBL] [Abstract][Full Text] [Related]
2. Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants.
Pestinger V; Smith M; Sillo T; Findlay JM; Laes JF; Martin G; Middleton G; Taniere P; Beggs AD
Mol Diagn Ther; 2020 Jun; 24(3):339-349. PubMed ID: 32306292
[TBL] [Abstract][Full Text] [Related]
3. Detection of Circulating Tumor DNA with a Single-Molecule Sequencing Analysis Validated for Targeted and Immunotherapy Selection.
Atkins A; Gupta P; Zhang BM; Tsai WS; Lucas J; Javey M; Vora A; Mei R
Mol Diagn Ther; 2019 Aug; 23(4):521-535. PubMed ID: 31209714
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive NGS Panel Validation for the Identification of Actionable Alterations in Adult Solid Tumors.
Martínez-Fernández P; Pose P; Dolz-Gaitón R; García A; Trigo-Sánchez I; Rodríguez-Zarco E; Garcia-Ruiz M; Barba I; Izquierdo-García M; Valero-Garcia J; Ruiz C; Lázaro M; Carbonell P; Gargallo P; Méndez C; Ríos-Martín JJ; Palmeiro-Uriach A; Camarasa-Lillo N; Forteza-Vila J; Calabria I
J Pers Med; 2021 Apr; 11(5):. PubMed ID: 33947144
[TBL] [Abstract][Full Text] [Related]
5. Analytical validation and clinical utilization of K-4CARE™: a comprehensive genomic profiling assay with personalized MRD detection.
Nguyen Hoang TP; Nguyen TA; Tran NHB; Nguyen Hoang VA; Thi Dao HT; Tran VU; Nguyen YN; Nguyen AT; Nguyen Thi CT; Do Thi TT; Nguyen DS; Nguyen HN; Giang H; Tu LN
Front Mol Biosci; 2024; 11():1334808. PubMed ID: 38404964
[No Abstract] [Full Text] [Related]
6. Molecular profiling of male breast cancer by multigene panel testing: Implications for precision oncology.
Valentini V; Silvestri V; Bucalo A; Conti G; Karimi M; Di Francesco L; Pomati G; Mezi S; Cerbelli B; Pignataro MG; Nicolussi A; Coppa A; D'Amati G; Giannini G; Ottini L
Front Oncol; 2022; 12():1092201. PubMed ID: 36686738
[TBL] [Abstract][Full Text] [Related]
7. Validation and implementation of a modular targeted capture assay for the detection of clinically significant molecular oncology alterations.
Kuo AJ; Paulson VA; Hempelmann JA; Beightol M; Todhunter S; Colbert BG; Salipante SJ; Konnick EQ; Pritchard CC; Lockwood CM
Pract Lab Med; 2020 Mar; 19():e00153. PubMed ID: 32123717
[TBL] [Abstract][Full Text] [Related]
8. Analytical validation and implementation of a pan cancer next-generation sequencing panel, CANSeq
Schilter KF; Smith BA; Nie Q; Stoll K; Felix JC; Jarzembowski JA; Reddi HV
Front Genet; 2023; 14():1067457. PubMed ID: 36845394
[TBL] [Abstract][Full Text] [Related]
9. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.
Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W
Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745
[TBL] [Abstract][Full Text] [Related]
10. Validation and Clinical Application of ONCOaccuPanel for Targeted Next-Generation Sequencing of Solid Tumors.
Kim M; Lee C; Hong J; Kim J; Jeong JY; Park NJ; Kim JE; Park JY
Cancer Res Treat; 2023 Apr; 55(2):429-441. PubMed ID: 36470260
[TBL] [Abstract][Full Text] [Related]
11. An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing.
Malhotra R; Javle V; Tanwar N; Gowda P; Varghese L; K A; Madhusudhan N; Jaiswal N; K S B; Chatterjee M; Prabhash K; Sreekanthreddy P; Rishi KD; Goswami HM; Veldore VH
Front Oncol; 2023; 13():1002792. PubMed ID: 36994199
[TBL] [Abstract][Full Text] [Related]
12. Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.
Milbury CA; Creeden J; Yip WK; Smith DL; Pattani V; Maxwell K; Sawchyn B; Gjoerup O; Meng W; Skoletsky J; Concepcion AD; Tang Y; Bai X; Dewal N; Ma P; Bailey ST; Thornton J; Pavlick DC; Frampton GM; Lieber D; White J; Burns C; Vietz C
PLoS One; 2022; 17(3):e0264138. PubMed ID: 35294956
[TBL] [Abstract][Full Text] [Related]
13. A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors.
Conroy JM; Pabla S; Glenn ST; Seager RJ; Van Roey E; Gao S; Burgher B; Andreas J; Giamo V; Mallon M; Lee YH; DePietro P; Nesline M; Wang Y; Lenzo FL; Klein R; Zhang S
PLoS One; 2021; 16(12):e0260089. PubMed ID: 34855780
[TBL] [Abstract][Full Text] [Related]
14. Guideline-Adherent Clinical Validation of a Comprehensive 170-Gene DNA/RNA Panel for Determination of Small Variants, Copy Number Variations, Splice Variants, and Fusions on a Next-Generation Sequencing Platform in the CLIA Setting.
Boyle TA; Mondal AK; Saeed-Vafa D; Ananth S; Ahluwalia P; Kothapalli R; Chaubey A; Roberts E; Qin D; Magliocco AM; Rojiani AM; Kolhe R
Front Genet; 2021; 12():503830. PubMed ID: 34093633
[TBL] [Abstract][Full Text] [Related]
15. Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer.
Claerhout S; Lehnert S; Vander Borght S; Spans L; Dooms C; Wauters E; Vansteenkiste J; Weynand B; Deraedt K; Bourgain C; Vanden Bempt I
Lung Cancer; 2022 Apr; 166():242-249. PubMed ID: 35378489
[TBL] [Abstract][Full Text] [Related]
16. Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB
Ramos-Paradas J; Hernández-Prieto S; Lora D; Sanchez E; Rosado A; Caniego-Casas T; Carrizo N; Enguita AB; Muñoz-Jimenez MT; Rodriguez B; Perez-Gonzalez U; Gómez-Sánchez D; Ferrer I; Ponce Aix S; Nuñez Buiza Á; Garrido P; Palacios J; Lopez-Rios F; Garrido-Martin EM; Paz-Ares L
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963008
[TBL] [Abstract][Full Text] [Related]
17. European Real-World Assessment of the Clinical Validity of a CE-IVD Panel for Ultra-Fast Next-Generation Sequencing in Solid Tumors.
Normanno N; Machado JC; Pescarmona E; Buglioni S; Navarro L; Esposito Abate R; Ferro A; Mensink R; Lambiase M; Lespinet-Fabre V; Calgua B; Jermann PM; Ilié M; Hofman P
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762091
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to Pembrolizumab.
Wei B; Kang J; Kibukawa M; Arreaza G; Maguire M; Chen L; Qiu P; Lang L; Aurora-Garg D; Cristescu R; Levitan D
J Mol Diagn; 2022 Jun; 24(6):600-608. PubMed ID: 35218944
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a Hybrid Capture-Based Pan-Cancer Panel for Analysis of Treatment Stratifying Oncogenic Aberrations and Processes.
Kroeze LI; de Voer RM; Kamping EJ; von Rhein D; Jansen EAM; Hermsen MJW; Barberis MCP; Botling J; Garrido-Martin EM; Haller F; Lacroix L; Maes B; Merkelbach-Bruse S; Pestinger V; Pfarr N; Stenzinger A; van den Heuvel MM; Grünberg K; Ligtenberg MJL
J Mol Diagn; 2020 Jun; 22(6):757-769. PubMed ID: 32205293
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a multigene variant profiling assay to guide targeted and immuno therapy selection in solid tumors.
Akolkar D; Patil D; Srivastava N; Patil R; Datta V; Apurwa S; Yashwante N; Dhasarathan R; Gosavi R; John J; Khan S; Jadhav N; Mene P; Ahire D; Pawar S; Bodke H; Sahoo S; Nile A; Saindane D; Darokar H; Devhare P; Srinivasan A; Datar R
PLoS One; 2021; 16(2):e0246048. PubMed ID: 33556149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
